Beth L. Cobb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beth L. Cobb has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Bahram Namjou
Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center
2 shared publications - Ingrid A. Holm
Department of Pediatrics, Harvard Medical School , Boston, MA 02115
2 shared publications - Aaron Scrol
Kaiser Permanente, Seattle, WA 98101, USA
1 shared publication - Aleksey Porollo
Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine , Cincinnati, OH 45267
1 shared publication - Alexander Fedotov
Irving Institute for Clinical and Translational Research, Columbia University, New York, NY 10025, USA
1 shared publication - Ali G. Gharavi
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA
1 shared publication
Latest Publications
- Open Access
- 3 January 2018
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 8 (1) , 2
Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience
We examined the Institutional Review Board (IRB) process at 9 academic institutions in the electronic Medical Records and Genomics (eMERGE) Network, for proposed electronic health record-based genomic medicine studies, to identify common questions and concerns. Sequencing of 109 disease related genes and genotyping of 14 actionable variants is being performed in ~28,100 participants from the 9 sites. Pathogenic/likely pathogenic variants in actionable genes are being returned to study participants. We examined each site’s research protocols, informed-consent materials, and interactions with IRB staff. Research staff at each site completed questionnaires regarding their IRB interactions. The time to prepare protocols for IRB submission, number of revisions and time to approval ranged from 10–261 days, 0–11, and 11–90 days, respectively. IRB recommendations related to the readability of informed consent materials, specifying the full range of potential risks, providing options for receiving limited results or withdrawal, sharing of information with family members, and establishing the mechanisms to answer participant questions. IRBs reviewing studies that involve the return of results from genomic sequencing have a diverse array of concerns, and anticipating these concerns can help investigators to more effectively engage IRBs.
- 3 January 2018
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 8 (1) , 2
Open AccessEthical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience
We examined the Institutional Review Board (IRB) process at 9 academic institutions in the electronic Medical Records and Genomics (eMERGE) Network, for proposed electronic health record-based genomic medicine studies, to identify common questions and concerns. Sequencing of 109 disease related genes and genotyping of 14 actionable variants is being performed in ~28,100 participants from the 9 sites. Pathogenic/likely pathogenic variants in actionable genes are being returned to study participants. We examined each site’s research protocols, informed-consent materials, and interactions with IRB staff. Research staff at each site completed questionnaires regarding their IRB interactions. The time to prepare protocols for IRB submission, number of revisions and time to approval ranged from 10–261 days, 0–11, and 11–90 days, respectively. IRB recommendations related to the readability of informed consent materials, specifying the full range of potential risks, providing options for receiving limited results or withdrawal, sharing of information with family members, and establishing the mechanisms to answer participant questions. IRBs reviewing studies that involve the return of results from genomic sequencing have a diverse array of concerns, and anticipating these concerns can help investigators to more effectively engage IRBs.
- Open Access
- 18 November 2014
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 5, 401
Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis
Objective: We report the first pediatric specific Phenome-Wide Association Study (PheWAS) using electronic medical records (EMRs). Given the early success of PheWAS in adult populations, we investigated the feasibility of this approach in pediatric cohorts. Method: Data on 5049 samples of European ancestry were obtained from the Electronic Medical Records (EMRs) of two large academic centers in five different genotyped cohorts. After standard quality controls, removing missing data and outliers based on principal components (PC) analyses, 4268 samples were used for the PheWAS study. We scanned for associations between 2476 single-nucleotide polymorphisms (SNP) with available genotyping data from previously published GWAS studies and 539 EMR-derived phenotypes. The false discovery rate was calculated and, for any new PheWAS findings, a permutation approach was implemented. Results: This PheWAS replicated a variety of common variants (MAF>10%) with prior GWAS associations in our pediatric cohorts including Juvenile Rheumatoid Arthritis (JIA), Asthma, Autism and Pervasive Developmental Disorder (PDD) and Type 1 Diabetes with a false discovery rate < 0.05 and power of study above 80%. In addition, several new PheWAS findings included a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p=4.33x10-7, OR=1.70, 95%CI=1.38-2.09), association at vicinity of (PLCL1, PRIP-1) gene for developmental delays and speech disorder (best SNP rs1595825, p=1.13x10-8, OR=0.65(0.57-0.76)), a cluster of SNP associations in the IL5-IL13 region, previously implicated in Asthma, Allergy, and Eosinophilia, with Eosinophilic Esophagitis (EE) (best SNP rs12653750, p=3.03x10-9, OR=1.73 95%CI=(1.44-2.07)) and association of variants in GCKR and JAZF1, responsible for metabolic disease and diabetes in adults with allergic rhinitis in our pediatric cohorts (best SNP rs780093, p=2.18x10-5, OR=1.39, 95%CI=(1.19-1.61)). Conclusion: By using the PheWAS approach and
- 18 November 2014
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 5, 401
Open AccessPhenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis
Objective: We report the first pediatric specific Phenome-Wide Association Study (PheWAS) using electronic medical records (EMRs). Given the early success of PheWAS in adult populations, we investigated the feasibility of this approach in pediatric cohorts. Method: Data on 5049 samples of European ancestry were obtained from the Electronic Medical Records (EMRs) of two large academic centers in five different genotyped cohorts. After standard quality controls, removing missing data and outliers based on principal components (PC) analyses, 4268 samples were used for the PheWAS study. We scanned for associations between 2476 single-nucleotide polymorphisms (SNP) with available genotyping data from previously published GWAS studies and 539 EMR-derived phenotypes. The false discovery rate was calculated and, for any new PheWAS findings, a permutation approach was implemented. Results: This PheWAS replicated a variety of common variants (MAF>10%) with prior GWAS associations in our pediatric cohorts including Juvenile Rheumatoid Arthritis (JIA), Asthma, Autism and Pervasive Developmental Disorder (PDD) and Type 1 Diabetes with a false discovery rate < 0.05 and power of study above 80%. In addition, several new PheWAS findings included a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p=4.33x10-7, OR=1.70, 95%CI=1.38-2.09), association at vicinity of (PLCL1, PRIP-1) gene for developmental delays and speech disorder (best SNP rs1595825, p=1.13x10-8, OR=0.65(0.57-0.76)), a cluster of SNP associations in the IL5-IL13 region, previously implicated in Asthma, Allergy, and Eosinophilia, with Eosinophilic Esophagitis (EE) (best SNP rs12653750, p=3.03x10-9, OR=1.73 95%CI=(1.44-2.07)) and association of variants in GCKR and JAZF1, responsible for metabolic disease and diabetes in adults with allergic rhinitis in our pediatric cohorts (best SNP rs780093, p=2.18x10-5, OR=1.39, 95%CI=(1.19-1.61)). Conclusion: By using the PheWAS approach and